Anixa Biosciences’ (ANIX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX) in a research note issued to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $7.00 price objective on the stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Anixa Biosciences in a research note on Wednesday, January 22nd.

Anixa Biosciences Stock Performance

Shares of NASDAQ:ANIX opened at $3.17 on Tuesday. The firm has a 50 day simple moving average of $2.71 and a 200 day simple moving average of $3.05. Anixa Biosciences has a 52 week low of $2.07 and a 52 week high of $4.20. The company has a market cap of $102.07 million, a PE ratio of -8.13 and a beta of 0.93.

Anixa Biosciences (NASDAQ:ANIX) last released its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. On average, equities analysts predict that Anixa Biosciences will post -0.46 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Lewis H. Titterton, Jr. acquired 10,000 shares of the stock in a transaction dated Friday, January 17th. The shares were acquired at an average price of $2.57 per share, with a total value of $25,700.00. Following the acquisition, the director now owns 922,334 shares in the company, valued at approximately $2,370,398.38. The trade was a 1.10 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Amit Kumar acquired 43,000 shares of Anixa Biosciences stock in a transaction dated Wednesday, January 15th. The stock was purchased at an average price of $2.23 per share, with a total value of $95,890.00. Following the completion of the purchase, the chief executive officer now directly owns 559,925 shares of the company’s stock, valued at $1,248,632.75. The trade was a 8.32 % increase in their position. The disclosure for this purchase can be found here. Insiders acquired 75,289 shares of company stock valued at $177,021 over the last ninety days. Corporate insiders own 25.30% of the company’s stock.

Hedge Funds Weigh In On Anixa Biosciences

Several large investors have recently made changes to their positions in ANIX. Millennium Management LLC bought a new position in Anixa Biosciences in the 4th quarter worth approximately $26,000. Virtu Financial LLC acquired a new stake in shares of Anixa Biosciences in the third quarter worth $34,000. Renaissance Technologies LLC increased its position in Anixa Biosciences by 36.5% during the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company’s stock worth $34,000 after acquiring an additional 3,900 shares during the period. Prosperity Wealth Management Inc. acquired a new position in shares of Anixa Biosciences during the fourth quarter valued at about $54,000. Finally, Jane Street Group LLC acquired a new position in Anixa Biosciences in the 4th quarter valued at approximately $67,000. Institutional investors and hedge funds own 29.13% of the company’s stock.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.